Text Size

Pictorial Representation of Illness and Self Measure (PRISM)

This study is currently recruiting participants.
Verified October 2012 by University of Oxford
Sponsor:
Collaborator:
UCB, Inc.
Information provided by (Responsible Party):
University of Oxford
ClinicalTrials.gov Identifier:
NCT01707186
First received: October 11, 2012
Last updated: October 19, 2012
Last verified: October 2012
History of Changes
  Purpose

PRISM (Pictorial Representation of Illness and Self Measure) has been developed since the mid-1990s; the task was first developed as a simple measure of how a person was coping with his or her experience of illness. This is an international, multicentre study to evaluate the PRISM tool for the assessment of suffering in rheumatoid arthritis at different stages of the illness and the effect of treatment intervention. There are 5 sites: Berlin, Oxford, Limoges, Montreal and Queensland. The study will recruit 200 patients in total.

In addition to the procedures for the patient's routine clinical visit, the patients will be invited to answer a series of questionnaires and donate 20ml blood sample. Patients will be asked to attend 3 times over 24 weeks


Condition
Rheumatoid Arthritis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Pictorial Representation of Illness and Self Measure

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Oxford:

Study Start Date: October 2012
Groups/Cohorts
Group 1A
Early phase, requiring change in treatment
Group 2
Established phase, stable treatment
Group 2A
Established phase, requiring a change in treatment
Group 1
Early phase, stable treatment

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Sampling Method:   Non-Probability Sample
Study Population

Patients with rheumatoid arthritis from hospital clinics

Criteria

Inclusion Criteria:

  • Participant is willing and able to give informed consent for participation in the study.
  • Male or Female, aged 18 years or above.
  • Written confirmed diagnosed of rheumatoid arthritis

Exclusion Criteria:

  • A diagnosis of any of the following:
  • Multiple sclerosis
  • Motor neurone disease
  • Parkinson's disease
  • Alzheimer's disease
  • Depression or anxiety disorders as identified using the Patient depression screening questions from the patient health questionnaire 9 (PHQ9).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01707186

Contacts
Contact: Catherine McClinton +441865 737838 catherine.mcclinton@kennedy.ox.ac.uk

Locations
United Kingdom
Nuffield Orthopaedic Centre Recruiting
Oxford, United Kingdom, OX3 7HE
Contact: Catherine McClinton     +441865 737838     catherine.mcclinton@kennedy.ox.ac.uk    
Contact: Peter Taylor     +441865 227323     peter.taylor@kennedy.ox.ac.uk    
Principal Investigator: Peter C Taylor, FRCP. PhD            
Sponsors and Collaborators
University of Oxford
UCB, Inc.
Investigators
Principal Investigator: Peter Taylor, FRCP, PhD University of Oxford
  More Information

No publications provided

Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT01707186     History of Changes
Other Study ID Numbers: 2010930
Study First Received: October 11, 2012
Last Updated: October 19, 2012
Health Authority: United Kingdom: Research Ethics Committee
United Kingdom: National Health Service

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
 Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on June 18, 2013